Seroprevalence of pertussis in Senegal: a prospective study

PLoS One. 2012;7(10):e48684. doi: 10.1371/journal.pone.0048684. Epub 2012 Oct 31.

Abstract

Background: Pertussis, also known as whooping cough, is a vaccine-preventable respiratory disease caused by Bordetella pertussis infection, against which Senegalese children are immunized with the diphtheria-tetanus-whole cell pertussis vaccine (DTwP). Seroepidemiology of pertussis has been widely described in industrialized countries, but rare are the studies referring to it in developing countries.

Methods: We conducted a longitudinal survey in Northern Senegal to investigate the epidemiology of B. pertussis by evaluating the IgG antibody (Ab) response against pertussis toxin (PT). A cohort of 410 children aged 1 to 9 from five villages in the Middle Senegal River Valley were followed-up for 18 months. During that period, five visits were made to assess the immunological status of the children.

Principal findings: PT-specific IgG responses were significantly different according to age. Until the age of 3, there was a decrease in the Ab response, which then increased in the older groups. Assessment of IgG antibodies to PT (IgG-PT) suggested evidence of recent exposures to the pathogen. Surprisingly, in one of the five villages the average Ab response to PT was very low at all ages during the first 6 months of the study. At the third visit, IgG-PT concentrations peaked to very high levels, to slightly decline at the end of the survey. This indicates an outbreak of B. pertussis, whereas in the other villages a pertussis endemic profile could be observed.

Conclusions: Pertussis is endemic in Northern Senegal despite the introduction of vaccination. The circulation of the bacteria seems to differ between geographic locations and over time. A more complete understanding of the epidemiology of pertussis and its environmental determinants could provide information to adapt vaccination programs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bacterial / blood
  • Antibodies, Bacterial / immunology
  • Bordetella pertussis / immunology*
  • Child
  • Child, Preschool
  • Developing Countries
  • Diphtheria-Tetanus-Pertussis Vaccine / administration & dosage
  • Diphtheria-Tetanus-Pertussis Vaccine / immunology*
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology
  • Infant
  • Male
  • Pertussis Toxin / immunology*
  • Poliovirus Vaccine, Inactivated / administration & dosage
  • Poliovirus Vaccine, Inactivated / immunology*
  • Prospective Studies
  • Senegal / epidemiology
  • Seroepidemiologic Studies
  • Time Factors
  • Vaccines, Combined / administration & dosage
  • Vaccines, Combined / immunology
  • Whooping Cough / epidemiology
  • Whooping Cough / immunology*
  • Whooping Cough / prevention & control

Substances

  • Antibodies, Bacterial
  • DTPP vaccine
  • Diphtheria-Tetanus-Pertussis Vaccine
  • Immunoglobulin G
  • Poliovirus Vaccine, Inactivated
  • Vaccines, Combined
  • Pertussis Toxin

Grants and funding

Lobna Gaayeb received support from the French Region Nord-Pas de Calais (http://www.nordpasdecalais.fr) and the Pasteur Institute of Lille (France) (http://www.pasteur-lille.fr). EPLS Biomedical Research Centre (http://www.espoir-sante.org) supported field investigation in the frame of the PAL-Fleuve program ( http://www.espoir-sante.org/etudes/en-cours/palfleuve.html). CIIL (http://u1019.lille.inserm.fr) provided support for the achievement of the immunological assays. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.